预约演示

Xencor pulls back from Genentech cancer pact to cut costs as CytomX drops ex-AbbVie ADC

2023-11-08

交易

临床1期抗体药物偶联物临床2期临床终止引进/卖出

Xencor is rethinking its plans for three programs to extend its runway into 2027.

Xencor and CytomX Therapeutics have taken a scalpel to their pipelines, stopping work on an ex-AbbVie antibody-drug conjugate (ADC) and pulling back from a co-development deal with Genentech to focus cash on other projects.

Xencored toCytomX Therapeuticsmaking more substantial changes to its strategy. Seeking to extenAbbVierunway into 2027, Xencor is rethinking its plans for three programs, including tGenentechcollaboration it entered into with Roche's Genentech unit in 2019. Since forming the deal, Xencor has funded 45% of the worldwide development costs of XmAb306 and other IL-15 assets. Now, the biotech is opting out of cost sharing.

Genentech haCytomXd Xencortency-reduced IL15/IL15Rα-Fc fusion protein XmAb306 into a set of phase 1 trials in various cXencor in combination with drugs including its checkpoint inhibitIL-15centriq. Xencor has previously warneRocheestGenentechits support for the program, which woulXencor secured it a 45% share of net profits from sales, mayXmAb306e it “to inIL-15ubstantial costs in excess of available resources.”

Genentechsclosed the change to the IL-15 collaboration alongside updatXmAb306ts plans for vudalimab and XmAb104. Citincancersrapidly changing competitive environment,” the biotech revealeTecentriqtoXencorthe gynecologic tumor cohorts in the monotherapy study of its PD-1xCTLA-4 bispecific vudalimab. Work on other indications is continuing.

XencorAb104 program is stopping altIL-15er. Xencor decided to halt internal development onvudalimabafterXmAb104rom phase 1 expansion cohorts fell short of the efficacy criteria for progressing further. The stgynecologic tumorolled patients with microsatellite stable colorectal cancer.vudalimab

XencXmAb104ed details of its updated strategXencortes before CytomX provided an update on CXmAb104 a CD71-directed ADC. AbbVie walked away from CX-2029 in March, terminating the pact after getting a look at results from a phase 2 trial.microsatellite stable colorectal cancer

Xencor reacquired the full rights to the program and began evCytomXng the next steps. LateCX-2029y, tCD71-directedvealedAbbVie will be no progress anytime soon, stating that “based on current priorities, [it] will not be directing significant additional investment in this program in the near-term.” The biotech made the call despite telling investors that it is “encouraged by the anti-tumor activity.”

CytomXr company making program cuts is Genmab, which has axed an antibody-based therapy called GEN3009, according to a third quarter earnings report issued Tuesday. The bispecific was created using the company's DuoHexaBody technology targeting CD37.tumor

Genmab had been testing GEN3009 in a phGenmab2 trial for B-cell non-Hodgkin lymphomas. That trial has now been discontinued based on a strategic review of Genmab's portfolio rather than safety or regulatory concerns, the company noted.CD37